Baxter International Inc. (BAX:NYSE) sees a new revenue source in vaccines and a multi-year opportunity in H1N1 flu vaccines. The healthcare company expects to see $30 million to $40 million of revenue in the fourth quarter from the H1N1 vaccine.
Baxter Chief Executive Robert Parkinson believes this is a business opportunity that will continue. Future revenue will be based on many factors, including further improvements of the vaccine and the severity of the strain.
For the complete story on the multiyear opportunity, read Debra Sherman’s article.
Hits: 346
Comments (0)
Write comment
